Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of neoadjuvant 'immunoradiation' (durvalumab or durvalumab plus
tremelimumab) administered every 4 weeks for 2 doses, concurrently with standard thoracic
radiation (RT) (45Gy in 25 fractions), with one dose of immunotherapy alone delivered in the
pre-surgical window, prior to surgical resection, for patients with stage IIIA NSCLC that is
deemed resectable with a lobectomy by a thoracic surgeon. If preliminary safety of the
durvalumab/thoracic RT combination is established, a second cohort investigating the
combination of durvalumab/tremelimumab/thoracic RT prior to surgical resection will be
opened. After surgical resection, patients may receive standard adjuvant chemotherapy, as
deemed appropriate by the treating investigator.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins